Close Menu

Prostate Cancer

News and reporting on prostate cancer.

Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.

Proceeds will be used to support studies for regulatory submissions to the FDA for the company's metastatic breast cancer test, among other things.

Cigna is the first national private payor to provider coverage for the Decipher tests, which provide a genomic assessment of tumor aggressiveness.

The researchers used 10X Genomics' linked-read genome sequencing approach to home in on rearrangements that affect the androgen receptor locus and its enhancer.

Using data for more than 140,000 individuals, researchers narrowed in on 63 new prostate cancer-associated loci and established a polygenic score linked to enhanced risk.

A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.

The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.

Exome sequencing on tumors from metastatic, castration-resistant prostate cancer cases responding to immunotherapy led to homologous recombination defects.

In a pan-cancer analysis, Lynch syndrome genes were mutated more often than anticipated in tumors with high or intermediate levels of microsatellite instability.

Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.